The inhibition of XPNPEP2 has been demonstrated to elevate endogenous bradykinin levels, thereby improving cardiovascular dilation function and mitigating cardiac injury associated with ischemia/reperfusion (Erşahin et al., 2005). This evidence concerns the gene XPNPEP2 and ischemia.